AVNS · As filed with the SEC
Avanos Medical balance sheet, by fiscal year
The statement as Avanos Medical presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
CONSOLIDATED BALANCE SHEETS · USD
| USD | FY2025 Dec 31, 2025 | FY2024 Dec 31, 2024 | FY2023 Dec 31, 2023 | FY2022 Dec 31, 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| Current Assets | ||||
| Cash and cash equivalents | 89,800,000 | 107,700,000 | 87,700,000 | 127,700,000 |
| Accounts receivable, net of allowances | 103,800,000 | 132,800,000 | 142,800,000 | 167,900,000 |
| Inventories | 148,000,000 | 138,800,000 | 163,200,000 | 190,300,000 |
| Prepaid and other current assets | 13,800,000 | 14,100,000 | 28,800,000 | 13,900,000 |
| Assets held for sale | — | 0 | 64,500,000 | — |
| Total Current Assets | 355,400,000 | 393,400,000 | 487,000,000 | 499,800,000 |
| Property, Plant and Equipment, net | 113,400,000 | 110,700,000 | 117,200,000 | 163,900,000 |
| Operating Lease Right-of-Use Assets | 27,600,000 | 34,100,000 | 26,800,000 | 30,600,000 |
| Goodwill | 394,900,000 | 455,600,000 | 796,100,000 | 819,400,000 |
| Other Intangible Assets, net | 117,800,000 | 112,300,000 | 239,500,000 | 251,000,000 |
| Deferred Tax Assets | 33,100,000 | 24,900,000 | 6,500,000 | 4,600,000 |
| Other Assets | 31,500,000 | 23,200,000 | 19,300,000 | 17,600,000 |
| TOTAL ASSETS | 1,073,700,000 | 1,154,200,000 | 1,692,400,000 | 1,786,900,000 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||
| Current Liabilities | ||||
| Current portion of long-term debt | 10,200,000 | 9,400,000 | 8,600,000 | 6,200,000 |
| Current portion of operating lease liabilities | 8,200,000 | 10,900,000 | 12,800,000 | 12,800,000 |
| Trade accounts payable | 55,500,000 | 54,300,000 | 56,300,000 | 67,900,000 |
| Accrued expenses | 91,300,000 | 91,300,000 | 93,200,000 | 98,900,000 |
| Liabilities held for sale | — | 0 | 63,700,000 | — |
| Total Current Liabilities | 165,200,000 | 165,900,000 | 234,600,000 | 185,800,000 |
| Long-Term Debt | — | — | — | 226,300,000 |
| Long-Term Debt | 90,300,000 | 125,300,000 | 159,400,000 | — |
| Operating Lease Liabilities | 20,400,000 | 24,600,000 | 28,300,000 | 34,700,000 |
| Deferred Tax Liabilities | 6,100,000 | 5,500,000 | 23,800,000 | 25,400,000 |
| Other Long-Term Liabilities | 13,500,000 | 4,400,000 | 10,000,000 | 23,500,000 |
| Total Liabilities | 295,500,000 | 325,700,000 | 456,100,000 | 495,700,000 |
| Stockholders’ Equity | ||||
| Preferred stock - $0.01 par value - authorized 20,000,000 shares, none issued | 0 | 0 | 0 | 0 |
| Common stock - $0.01 par value - authorized 300,000,000 shares, 46,456,462 outstanding at December 31, 2025 and 45,962,627 outstanding at December 31, 2024 | 500,000 | 500,000 | 500,000 | 500,000 |
| Additional paid-in capital | 1,691,900,000 | 1,678,600,000 | 1,663,600,000 | 1,646,400,000 |
| Accumulated deficit | (779,900,000) | (707,000,000) | (314,900,000) | (253,100,000) |
| Treasury stock | (102,300,000) | (99,000,000) | (85,900,000) | (66,800,000) |
| Accumulated other comprehensive loss | (32,000,000) | (44,600,000) | (27,000,000) | (35,800,000) |
| Total Stockholders’ Equity | 778,200,000 | 828,500,000 | 1,236,300,000 | 1,291,200,000 |
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | 1,073,700,000 | 1,154,200,000 | 1,692,400,000 | 1,786,900,000 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.